Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak et al. · Journal of Clinical Oncology · 2009 · 2.2K citations

Medicine, Oncology, Pharmacology +13

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

Martin Gore, Cezary Szczylik, Camillo Porta et al. · British Journal of Cancer · 2015 · 191 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736)

Brian I. Rini, Joan H. Schiller, John P. Fruehauf et al. · Journal of Clinical Oncology · 2008 · 93 citations

Medicine, Oncology, Pharmacology +17

Sunitinib‐induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma

Juhana Rautiola, Frede Donskov, Katriina Peltola et al. · British Journal of Urology · 2014 · 57 citations · Full text

Medicine, Oncology, Pharmacology +13